Sangamo Announces AAV Capsid Data

Uncategorized

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

Announced additional progress towards strategic transformation into neurology-focused genomic medicine company. Focusing resources on proprietary epigenetic regulation therapies treating neurological diseases and novel AAV capsid delivery technologies.